newsfilter
← Latest News
PR Newswire·

NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference

  • NeuroSense Therapeutics CFO Or Eisenberg will attend the 5th Annual ROTH Healthcare Opportunities Conference on September 29, 2026, at The Metropolitan Club in New York City.
  • The executive will hold one-on-one & small-group investor meetings to discuss PrimeC clinical/regulatory progress & strategies for approval in Canada, the U.S., & other markets.
  • PrimeC is NeuroSense's lead oral therapy targeting neuroinflammation, oxidative stress, & dysregulated iron metabolism in ALS & Alzheimer's disease.
  • The company published Phase 2b PARADIGM study results in JAMA Neurology showing slowed functional decline & favorable biomarker changes.
  • NeuroSense received FDA clearance to launch the pivotal Phase 3 PARAGON trial in ALS & is collaborating on an optimized study design.
  • PrimeC consists of a fixed-dose combination of ciprofloxacin & celecoxib designed to inhibit neuron degeneration & disease progression.
  • Forward-looking statements warn of risks including potential trial delays, financing challenges, & failure to meet Nasdaq listing requirements.